Frederic Castinetti, MD, PhD, is Professor of Endocrinology at Aix-Marseille University, France. He received his PhD in Neuroscience from Aix-Marseille University, focusing on the roles of transcription factors in the development of combined pituitary hormone deficiencies. Prof Castinetti did a postdoctoral fellowship at the University of Michigan with Prof Sally Camper, where he used transgenic mouse models to investigate the roles of specific transcription factors in thyrotroph development and function. In parallel, his main clinical interests are pituitary and adrenal disorders. Prof Castinetti has been particularly interested in the medical management of hypercortisolism, early diagnosis of early recurrence of Cushing’s disease, and the long-term consequences of high glucocorticoid exposure. Prof Castinetti’s recent work has focused on the management of hereditary pheochromocytoma and medullary thyroid carcinoma, and more specifically multiple endocrine neoplasia type 2. In 2018, he was the coordinator of the French Endocrine Society guidelines on the diagnosis and management and endocrine dysfunctions induced by immunotherapy.
Disclosures: Prof Castinetti has received research grants and consultancy fees from HRA Pharma Rare Diseases, Novartis, Pfizer, Ipsen, and Recordati Rare Diseases.
Senior Clinical Lecturer in Endocrinology and Honorary Consultant Endocrinologist. Institute of Metabolism and Systems Research (IMSR), College of Medical and Dental Sciences, University of Birmingham; Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust; Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, UK
Niki Karavitaki is Senior Clinical Lecturer (University of Birmingham) and Honorary Consultant Endocrinologist (University Hospitals Birmingham NHS Foundation Trust). She was awarded Master’s in Neuroendocrinology with Distinction at the Imperial College of Science, Technology and Medicine, London. Following completion of her clinical training in Athens, she worked for 3 years as Research Fellow in Oxford under the supervision of Professor John Wass focusing on pituitary tumours. She was then appointed Consultant Endocrinologist at the Oxford Centre for Diabetes, Endocrinology and Metabolism where she expanded her research portfolio on pituitary disease. In 2015, she moved to Birmingham leading the academic Pituitary Theme and co-leading the NHS Pituitary Service, one of the largest in Europe. She has active involvement in national and international committees (Board of Directors of Pituitary Society, Executive Committee of European Neuroendocrine Association, Co-chair of Adrenal and Pituitary Special Interest Group of Endocrine Society, USA). Optimal management and long-term outcomes of Cushing’s remain one of her long-standing research interests.
Disclosures: Dr. Karavitaki has received research/educational grants and speaker/consultant fees from Pfizer, Ipsen, Novartis, HRA Pharma Rare Diseases, and Recordati Rare Diseases.
Greisa Vila is Associate Professor of Medicine at the Medical University of Vienna, Austria. She graduated at the University of Tirana, Albania, and obtained her doctor’s degree at the Ludwig Maximilian University of Munich, Germany in 2004 with a translational thesis on the role of Sonic hedgehog signaling on corticotroph function and pituitary adenomas. She previously worked in the Division of Endocrinology, Hospital Saint-Antoine, Paris (2000-2001) and the Neuroendocrinology Group of the Max-Planck-Institute of Psychiatry in Munich (2002-2005). She has been in the Division of Endocrinology, Vienna General Hospital, since 2006. Her primary clinical and research interests are pituitary diseases, and in particular neuroendocrine-metabolic interactions. In the field of hypercortisolism, she has contributed with translational studies on ACTH regulation and glucocorticoid function, as well as with clinical studies on acute and chronic comorbidities in patients with Cushing’s syndrome.
Disclosures: Prof. Dr Vila has received lecture and/or consulting fees from HRA Pharma Rare Diseases, Recordati, Takeda, Ipsen, Pfizer and Novo Nordisk, and has been a Research Investigator for studies sponsored by Novartis, Recordati, Corcept, Ipsen, Pfizer, Chiasma and Takeda.